Risk of tuberculosis reactivation during interleukin‐17 inhibitor therapy for psoriasis: a systematic review-Reference-Cited by-同舟云学术

Risk of tuberculosis reactivation during interleukin‐17 inhibitor therapy for psoriasis: a systematic review

Published:2020-03-15 Issue:7 Volume:34 Page:1449-1456
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Fowler E.¹^ORCID,Ghamrawi R.I.²,Ghiam N.¹,Liao W.³,Wu J.J.⁴^ORCID

Affiliation:

1. Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami FL USA

2. Edward Via College of Osteopathic Medicine Auburn AL USA

3. Department of Dermatology University of California San Francisco San Francisco CA USA

4. Dermatology Research and Education Foundation Irvine CA USA

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16254

Reference34 articles.

1. World Health Organization.Latent tuberculosis infection: Scaling up programmatic management of LTBI a critical action to achieve the WHO End TB Strategy targets[Internet] 2016. URLhttps://www.who.int/tb/challenges/ltbi_factsheet_25nov15.pdf?ua=1(last accessed: 26 August 2019).

2. Tuberculosis and interleukin blocking monoclonal antibodies: is there risk?;Kelsey A;Dermatol Online J,2018

3. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review

4. The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents

5. Impact of inhalational versus intravenous anaesthesia on early delirium and long-term survival in elderly patients after cancer surgery: study protocol of a multicentre, open-label, and randomised controlled trial

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus;Journal of the European Academy of Dermatology and Venereology;2024-08-16

2. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent;J BRAS PNEUMOL;2024

3. Evaluation of serial QuantiFERON‐TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐IL‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country;Australasian Journal of Dermatology;2024-07

4. The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis;Immunotherapy;2024-03-21

5. Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment;Dermatology and Therapy;2024-03-14